Alpha Tau Medical Ltd. (DRTS)
Oxford Ledge is still expanding full research coverage of DRTS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Alpha Tau Medical develops cancer treatment technology based on the Alpha DaRT platform founded by its CEO and academic inventors.
SEC filings
- 6-K Interim report (foreign private issuer) 2026-06-25
- 6-K Interim report (foreign private issuer) 2026-06-23
- 6-K Interim report (foreign private issuer) 2026-06-11
- 6-K Interim report (foreign private issuer) 2026-06-03
- 6-K Interim report (foreign private issuer) 2026-06-01
Source: SEC EDGAR.
Annual results
5 years of annual figures for DRTS, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$42.6M | -$0.53 |
| 2024 | — | -$31.8M | -$0.45 |
| 2023 | — | -$29.2M | -$0.42 |
| 2022 | — | -$33.8M | -$0.53 |
| 2021 | — | -$27.3M | -$0.67 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for DRTS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open DRTS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.